India faces a persistent challenge with rabies, a preventable disease that continues to cause fatalities due to failures in prevention and access to care. Concerns have been raised over counterfeit anti-rabies vaccines, with Indian Immunologicals Limited stating a single counterfeit batch was identified and removed, assuring authorized supplies are tested. The article highlights that rabies disproportionately affects marginalized populations, illustrating a broader gap where low- and middle-income countries, despite high disease burdens, conduct few genomic studies, impacting diagnostics and treatments.